These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3701536)

  • 1. Antibiotic activity in sputum.
    Levy J
    J Pediatr; 1986 May; 108(5 Pt 2):841-6. PubMed ID: 3701536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracheobronchitis due to Corynebacterium pseudodiphtheriticum.
    Craig TJ; Maguire FE; Wallace MR
    South Med J; 1991 Apr; 84(4):504-6. PubMed ID: 2014440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled antimicrobial therapy.
    O'Riordan T; Faris M
    Respir Care Clin N Am; 1999 Dec; 5(4):617-31. PubMed ID: 10565884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal.
    Nelson JD
    J Pediatr; 1985 Jun; 106(6):1030-4. PubMed ID: 3889252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tobramycin therapy of pulmonary infections in patients with cystic fibrosis.
    Hawley HB; Lewis RM; Swartz DR; Gump DW
    Curr Ther Res Clin Exp; 1974 May; 16(5):414-23. PubMed ID: 4209057
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary infections in children with cystic fibrosis.
    Stutman HR; Marks MI
    Semin Respir Infect; 1987 Sep; 2(3):166-76. PubMed ID: 3317617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibiotic therapy in cystic fibrosis. II Antibiotic strategy].
    Sermet-Gaudelus I; Ferroni A; Gaillard JL; Silly C; Chretiennot C; Lenoir G; Berche P
    Arch Pediatr; 2000 Jun; 7(6):645-56. PubMed ID: 10911533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum.
    Devereux G; Fraser-Pitt D; Robertson J; Devlin E; Mercer D; O'Neil D
    EBioMedicine; 2015 Oct; 2(10):1507-12. PubMed ID: 26629546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
    Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
    Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penetration of enoxacin into bronchial secretions.
    Fong IW; Vandenbroucke A; Simbul M
    Antimicrob Agents Chemother; 1987 May; 31(5):748-51. PubMed ID: 3475036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should We Treat Ventilator-Associated Tracheobronchitis with Antibiotics?
    Martin-Loeches I; Coakley JD; Nseir S
    Semin Respir Crit Care Med; 2017 Jun; 38(3):264-270. PubMed ID: 28578551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nosocomial tracheobronchitis.
    Nseir S; Ader F; Marquette CH
    Curr Opin Infect Dis; 2009 Apr; 22(2):148-53. PubMed ID: 19276882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspergillus Bronchitis in Patients with Cystic Fibrosis.
    Brandt C; Roehmel J; Rickerts V; Melichar V; Niemann N; Schwarz C
    Mycopathologia; 2018 Feb; 183(1):61-69. PubMed ID: 28819878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.
    Sajjan US; Tran LT; Sole N; Rovaldi C; Akiyama A; Friden PM; Forstner JF; Rothstein DM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3437-44. PubMed ID: 11709321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa.
    Nair CG; Chao C; Ryall B; Williams HD
    Lett Appl Microbiol; 2013 Feb; 56(2):149-54. PubMed ID: 23206221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis.
    Tunney MM; Klem ER; Fodor AA; Gilpin DF; Moriarty TF; McGrath SJ; Muhlebach MS; Boucher RC; Cardwell C; Doering G; Elborn JS; Wolfgang MC
    Thorax; 2011 Jul; 66(7):579-84. PubMed ID: 21270069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled antibiotics in cystic fibrosis: is there a therapeutic effect?
    MacLusky I; Levison H; Gold R; McLaughlin FJ
    J Pediatr; 1986 May; 108(5 Pt 2):861-5. PubMed ID: 3517274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes.
    Craven DE; Chroneou A; Zias N; Hjalmarson KI
    Chest; 2009 Feb; 135(2):521-528. PubMed ID: 18812452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.